Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.c

Pericardial effusion (w/wo tamponade)

Publications

Maral S, Bakanay SM, Kucuksahin O, Dilek I

Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019 Jul 30;;1078155219863469 — 2019 Jul 30 — 1078155219863469

Breccia M, Alimena G

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

Leukemia research 2013 Jun;37;713-20 — 2013 Jun — 713-20

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Hematological oncology 2013 Jun;31;103-9 — 2013 Jun — 103-9

Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlögl E, Valent P

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Haematologica 2011 Jan;96;163-6 — 2011 Jan — 163-6

Breccia M, Alimena G

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Expert opinion on drug safety 2010 Sep;9;713-21 — 2010 Sep — 713-21

Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Targeted oncology 2009 Apr;4;99-105 — 2009 Apr — 99-105